Healthcare · Medical - Pharmaceuticals
Price
$0.97
Market Cap
$12.4M
Employees
88
Beta
0.85
Avg Volume
200,598
CEO
Hermann Lübbert
Business Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Business History
Price Overview
Last updated: Jun 27, 2026 10:03am (just now)$0.97
+0.02 (+2.58%)
Day Range
$0.92 – $0.99
52-Week Range
$0.56 – $1.19
50-Day MA
$0.99
200-Day MA
$0.92
Volume
247,950.00
Share Structure
Outstanding
12,803,344.00
Float
10,888,091.00
Free Float
85.0%
High free float
— 85.0% of shares trade freely, ~15% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.93
Stock Price: $0.97
EPS (Diluted): -1.04
EPS (Diluted): -1.04
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.55
Stock Price: $0.97
Total Equity: $10.48M
Shares: 11,648,323
Total Equity: $10.48M
Shares: 11,648,323
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.38
Market Cap: $12.43M
Total Debt: $5.83M
Cash: $6.39M
EBITDA: -$9.19M
Total Debt: $5.83M
Cash: $6.39M
EBITDA: -$9.19M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$5.6M
Market Cap: $12.43M
Total Debt: $5.83M
Cash: $6.39M
Total Debt: $5.83M
Cash: $6.39M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.14
Stock Price: $0.97
Revenue: $41.71M
Shares: 11,648,323
Revenue: $41.71M
Shares: 11,648,323
EV/Sales (Total value vs revenue — works when P/E can't)
API0.13
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
78.7%
Gross Profit: $32.80M
Revenue: $41.71M
Revenue: $41.71M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-21.9%
Operating Income: -$9.15M
Revenue: $41.71M
Revenue: $41.71M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-25.3%
Net Income: -$10.54M
Revenue: $41.71M
Revenue: $41.71M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-476.7%
Net Income: -$10.54M
Total Equity: $10.48M
Total Equity: $10.48M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-62.1%
Operating Income: -$9.15M
Tax Rate: -0.2%
Equity: $10.48M
Total Debt: $5.83M
Cash: $6.39M
Tax Rate: -0.2%
Equity: $10.48M
Total Debt: $5.83M
Cash: $6.39M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.52
Current Assets: $18.08M
Current Liabilities: $11.90M
Current Liabilities: $11.90M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.56
Short-Term Debt: $0.00
Long-Term Debt: $5.83M
Total Debt: $5.83M
Total Equity: $10.48M
Long-Term Debt: $5.83M
Total Debt: $5.83M
Total Equity: $10.48M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$3.58
Revenue: $41.71M
Shares: 11,648,323
Shares: 11,648,323
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.90
Total Equity: $10.48M
Shares: 11,648,323
Shares: 11,648,323
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.15
Operating CF: -$13.36M
CapEx: -$2,000
Shares: 11,648,323
CapEx: -$2,000
Shares: 11,648,323
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.97
Stock Price: $0.97
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$10.54M
Net Income: -$10.54M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares BFRI against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 1:38pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $24.1M | $28.7M | $34.1M | $37.3M | $41.7M |
| Cost of Revenue | $12.7M | $15.2M | $17.4M | $18.6M | $8.9M |
| Gross Profit | $11.4M | $13.5M | $16.6M | $18.7M | $32.8M |
| Operating Expenses | $36.6M | $32.1M | $39.3M | $35.9M | $42.0M |
| Operating Income | -$25.2M | -$18.6M | -$22.7M | -$17.2M | -$9.1M |
| Net Income | -$37.7M | $-640,000 | -$20.1M | -$17.8M | -$10.5M |
| EBITDA | -$36.8M | $934,000 | -$18.5M | -$14.4M | -$9.2M |
| EPS | $-44.10 | $-0.61 | $-13.02 | $-3.22 | $-1.04 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 1:38pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $24.5M | $17.2M | $1.3M | $5.9M | $6.4M |
| Total Current Assets | $46.4M | $43.1M | $23.1M | $20.7M | $18.1M |
| Total Assets | $53.2M | $50.9M | $27.9M | $22.1M | $28.6M |
| Current Liabilities | $13.8M | $20.9M | $18.1M | $12.0M | $11.9M |
| Long-Term Debt | $0 | $0 | $0 | $4.1M | $5.8M |
| Total Liabilities | $41.9M | $27.0M | $23.1M | $17.7M | $18.1M |
| Total Equity | $11.3M | $23.9M | $4.8M | $4.4M | $10.5M |
| Retained Earnings | -$78.9M | -$79.5M | -$99.7M | -$117.4M | -$127.9M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 1:38pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$26.7M | -$16.2M | -$24.9M | -$10.3M | -$13.4M |
| Capital Expenditure | $-11,000 | $-38,000 | $-5,000 | $-60,000 | $-2,000 |
| Free Cash Flow | -$26.7M | -$16.2M | -$24.9M | -$10.3M | -$13.4M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $3.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $16.5M | -$7.3M | -$15.9M | $4.6M | $487,000 |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:03am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$52.7M $52.5M – $52.9M
|
$64.4M $63.8M – $65.0M
|
$81.4M $81.1M – $81.7M
|
$98.6M $98.2M – $98.9M
|
| EBITDA |
-$22.3M -$22.4M – -$22.2M
|
-$27.3M -$27.5M – -$27.0M
|
-$34.4M -$34.6M – -$34.3M
|
-$41.7M -$41.9M – -$41.6M
|
| Net Income |
$2.2M $2.2M – $2.2M
|
$2.6M $1.7M – $3.4M
|
$4.0M $3.9M – $4.0M
|
$6.2M $6.1M – $6.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 1:38pm (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +19.0% | +18.8% | +9.5% | +11.8% |
| Gross Profit Growth | +18.8% | +23.3% | +12.4% | +75.5% |
| Operating Income Growth | +26.3% | -22.0% | +24.1% | +46.8% |
| Net Income Growth | +98.3% | -3,045.5% | +11.8% | +40.7% |
| EBITDA Growth | +102.5% | -2,075.7% | +21.7% | +36.4% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 7:02am (3h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-04 | Weber Kevin Daniel | A-Award | 20,000.00 | $0.90 | $18,000 |
| 2026-03-05 | Luebbert Hermann | M-Exempt | 137,500.00 | $0.00 | $0 |
| 2026-03-04 | Luebbert Hermann | A-Award | 125,000.00 | $0.00 | $0 |
| 2026-03-04 | Luebbert Hermann | A-Award | 125,000.00 | $0.90 | $112,500 |
| 2026-03-05 | Luebbert Hermann | M-Exempt | 137,500.00 | $0.00 | $0 |
| 2026-03-05 | Leffler Eugene Frederick | M-Exempt | 87,500.00 | $0.00 | $0 |
| 2026-03-04 | Leffler Eugene Frederick | A-Award | 62,500.00 | $0.00 | $0 |
| 2026-03-04 | Leffler Eugene Frederick | A-Award | 62,500.00 | $0.90 | $56,250 |
| 2026-03-05 | Leffler Eugene Frederick | M-Exempt | 87,500.00 | $0.00 | $0 |
| 2026-03-04 | Lanckriet Heikki | A-Award | 20,000.00 | $0.90 | $18,000 |
| 2026-03-04 | Hoffman Beth J. | A-Award | 20,000.00 | $0.90 | $18,000 |
| 2026-03-04 | Jones George Patrick | A-Award | 50,000.00 | $0.00 | $0 |
| 2026-03-04 | Jones George Patrick | A-Award | 50,000.00 | $0.90 | $45,000 |
| 2026-03-04 | BORER JOHN J III | A-Award | 20,000.00 | $0.90 | $18,000 |
| 2025-09-16 | Link Christian Alexander Ansgar | 0.00 | $0.00 | $0 | |
| 2025-09-16 | VV Beteiligungen Aktiengesellschaft | 0.00 | $0.00 | $0 | |
| 2025-09-16 | VV Beteiligungen Aktiengesellschaft | 0.00 | $0.00 | $0 | |
| 2025-09-16 | VV Beteiligungen Aktiengesellschaft | 4,831,172.00 | $0.62 | $3.0M | |
| 2025-09-16 | DELPHI UNTERNEHMENSBERATUNG AKTIENGESELLSCHAFT | 0.00 | $0.00 | $0 | |
| 2025-09-16 | DELPHI UNTERNEHMENSBERATUNG AKTIENGESELLSCHAFT | 0.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for BFRI — it's generated by the pipeline (
market-narrative step).
No community reviews yet for BFRI.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30